First Trust Advisors LP Has $4.41 Million Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

First Trust Advisors LP cut its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 13.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 47,824 shares of the medical instruments supplier's stock after selling 7,367 shares during the period. First Trust Advisors LP owned about 0.21% of LeMaitre Vascular worth $4,407,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Smartleaf Asset Management LLC grew its position in LeMaitre Vascular by 234.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock valued at $39,000 after acquiring an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC grew its holdings in shares of LeMaitre Vascular by 38.5% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock valued at $39,000 after purchasing an additional 117 shares during the last quarter. KBC Group NV increased its position in LeMaitre Vascular by 58.4% during the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock worth $102,000 after purchasing an additional 410 shares in the last quarter. Huntington National Bank lifted its stake in LeMaitre Vascular by 64.9% in the 4th quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock valued at $107,000 after purchasing an additional 455 shares during the last quarter. Finally, Empowered Funds LLC acquired a new stake in LeMaitre Vascular in the fourth quarter valued at approximately $150,000. Institutional investors own 84.64% of the company's stock.

Insider Buying and Selling at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,009 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares in the company, valued at $456,915.68. This trade represents a 26.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 10.79% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on LMAT. Lake Street Capital upped their price target on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price objective for the company. Finally, Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Five analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $98.14.

LeMaitre Vascular Price Performance

Shares of LMAT traded up $1.74 during trading hours on Monday, hitting $80.44. 355,694 shares of the stock were exchanged, compared to its average volume of 163,672. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $109.58. The business has a 50-day moving average of $85.58 and a 200-day moving average of $93.37. The firm has a market capitalization of $1.82 billion, a P/E ratio of 43.96, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.02). The business had revenue of $59.87 million during the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. LeMaitre Vascular's quarterly revenue was up 12.0% compared to the same quarter last year. During the same period last year, the firm posted $0.44 earnings per share. As a group, analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th will be issued a $0.20 dividend. The ex-dividend date is Thursday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.99%. LeMaitre Vascular's payout ratio is currently 41.24%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.